Home
Current Issue

Current Issue

Current Issue: Volume 4 (2026), Issue 2, Spring 2026 

Frequency: Quarterly (4 issues/year)

This is a peer-reviewed, open-access journal dedicated to the genomic and epigenomic drivers of cancer. We publish original research, methodological advances and critical reviews spanning tumour evolution, epigenetic regulation, liquid biopsy and precision oncology.

All articles are freely available on publication under a Creative Commons licence, with no article processing charges to authors.

  • Double Blind
  • Quarterly (4 issues/year)
  • Indexing and Abstracting: DOAJ · Scopus · PubMed Central

About Journal

More →
About

A Journal for Cancer Genomics

Peer-reviewed, open access, and free to read and to publish in — a demonstration journal built on JournalManager.

Who We Are

We publish original research on the genomic and epigenomic basis of cancer, alongside the computational methods that make that research possible. The journal is edited by working researchers, reviewed by working researchers, and read by them; every editorial decision is made by someone who could have written the paper themselves.

Founded as a quarterly, we publish four issues a year plus occasional special issues on a single theme. Accepted articles appear online as soon as they are ready rather than waiting for an issue to close, so a finished paper is never held back by a publication schedule.

2022
first issue
4
issues each year
18 days
median to first decision
0
charges to authors

What We Stand For

Open by default

Every article is free to read from the day it appears. Authors keep copyright and grant us only the right of first publication.

No charges

No submission fee, no page charge, no article processing charge. Publication is funded by the host institution.

Reproducible

Data in a public repository and code that runs are conditions of acceptance, not optional extras.

Fast and fair

Double-anonymised review, published timelines, and a route of appeal heard by an uninvolved editor.

What You Will Find Here

  • Research articles on tumour evolution, epigenetic regulation and structural variation
  • Single-cell, spatial and long-read studies of tumour heterogeneity
  • Biomarker and liquid-biopsy work aimed at earlier detection
  • Functional genomics, including CRISPR screens and synthetic-lethal interactions
  • Computational methods published with documented, runnable code
  • Registered Reports, reviewed before the results exist
  • Confirmatory and well-powered negative results
  • Benchmarking studies of methods already in wide use

How We Work

Submissions are screened within five working days and, if they go out, reviewed by at least two independent experts. Reviewers do not see who wrote the manuscript and authors do not see who reviewed it. The handling editor weighs the reports and decides; where reviewers split, a third is invited rather than the editor breaking the tie alone.

Editorial decisions rest with the editors. Neither the publisher, the owning institution nor any funder has a say in whether a manuscript is accepted, and no editor decides on a submission from their own institution or a recent collaborator.

Access, Licensing and Preservation

Articles are published under a Creative Commons licence, so anyone may read, redistribute and build on them with attribution. Authors retain copyright. Content is deposited with a persistent identifier and archived so that it remains available if the journal itself ever stops publishing.

A note on this site: this is a demonstration installation of JournalManager. The articles, issues, board members and news items are illustrative content, not real publications, and every one of them is editable from the admin panel.

Want to publish with us?

Read the Aims & Scope and the Guide for Authors, then submit from the Submit Paper menu.

Current Issue: Volume 4 (2026), Issue 2, Spring 2026 

More →

Keywords Cloud

News & Announcements